Immuron Limited (IMRN) 10-Year Financial Performance & Capital Metrics

IMRN • • Industrial / General

HealthcareBiotechnologyInfectious DiseasesAntibiotics & Bacterial Infections

AboutImmuron Limited, a biopharmaceutical company, researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It markets Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and reduce the symptoms of minor gastro-intestinal disorders, as well as for dietary supplement for digestive tract protection; and Protectyn, an immune supplement to maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III clinical trials to reduce the risk of contracting travelers' diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in clinical development stage focuses on treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and ETEC infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is based in Carlton, Australia.Show more

Revenue $7M +48.6%
EBITDA -$5M +8.0%
Net Income -$5M +24.8%
EPS (Diluted) -0.90 +26.2%
Gross Margin 65.39% -3.9%
EBITDA Margin -72.66% +38.1%
Operating Margin -73.34% +38.0%
Net Margin -71.58% +49.4%
ROE -50.3% -17.2%
ROIC -122.51% +45.5%
Debt/Equity 0.01 +6.8%
Interest Coverage -731.63 +4.5%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Strong 5Y sales CAGR of 23.7%
✓Trading at only 0.8x book value

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Negative free cash flow
✗Weak momentum: RS Rating 6 (bottom 6%)
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y21.94%

5Y23.67%

3Y111.96%

TTM61.05%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM23.48%

EPS CAGR

10Y-

5Y-

3Y-

TTM25.41%

ROCE

10Y Avg-62.61%

5Y Avg-33.55%

3Y Avg-34.36%

Latest-50.96%

Peer Comparison

Antibiotics & Bacterial Infections

Name	Market Cap	Current Price	P/E Ratio	Net Margin	ROE	Debt/Equity
PLRZPolyrizon Ltd.	16.19M	15.54	31.08		-5.21%
TOVXTheriva Biologics, Inc.	7.49M	0.21	-0.01		-388.69%	0.08
CTXRCitius Pharmaceuticals, Inc.	17.79M	0.86	-0.14	-258.23%	-59.6%	0.00
ACXPAcurx Pharmaceuticals, Inc.	6.32M	2.69	-0.15		-0.25%
ITRMIterum Therapeutics plc	17.16M	0.32	-0.26	-69.13%
ANTXAN2 Therapeutics, Inc.	34.25M	1.25	-0.73		-56.29%
MCRBSeres Therapeutics, Inc.	137.33M	15.18	-0.80	15.37%	12.34%	6.65
PYPDPolyPid Ltd.	73.03M	4.39	-0.89		-10.39%	1.25

Profit & Loss

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Sales/Revenue+	1M	1.4M	1.84M	2.39M	2.52M	145.78K	765.19K	1.8M	4.9M	7.29M
Revenue Growth %	-0%	0.39%	0.32%	0.3%	0.05%	-0.94%	4.25%	1.36%	1.72%	0.49%
Cost of Goods Sold+	305.61K	474.04K	582.29K	680.76K	688.84K	810.84K	241.69K	64.63K	1.57M	2.52M
COGS % of Revenue	0.31%	0.34%	0.32%	0.29%	0.27%	5.56%	0.32%	0.04%	0.32%	0.35%
Gross Profit+	695.47K	922.16K	1.26M	1.71M	1.83M	-665.06K	523.5K	1.74M	3.34M	4.77M
Gross Margin %	0.69%	0.66%	0.68%	0.71%	0.73%	-4.56%	0.68%	0.96%	0.68%	0.65%
Gross Profit Growth %	0.07%	0.33%	0.37%	0.35%	0.07%	-1.36%	1.79%	2.32%	0.92%	0.43%
Operating Expenses+	8.96M	9.31M	4.25M	6.36M	4.74M	7.71M	3.39M	5.31M	9.14M	10.11M
OpEx % of Revenue	8.95%	6.67%	2.31%	2.67%	1.88%	52.92%	4.43%	2.94%	1.86%	1.39%
Selling, General & Admin	5.33M	4.68M	4.1M	5.9M	4.04M	6.38M	3.94M	5.15M	6.59M	7.94M
SG&A % of Revenue	5.33%	3.35%	2.22%	2.47%	1.6%	43.78%	5.15%	2.85%	1.34%	1.09%
Research & Development	3.62M	4.63M	2.26M	1.04M	1.18M	1.37M	657.72K	2.59M	5.38M	3.6M
R&D % of Revenue	3.62%	3.32%	1.22%	0.44%	0.47%	9.38%	0.86%	1.44%	1.1%	0.49%
Other Operating Expenses	0	0	-2.11M	-583.86K	-485.01K	-34.58K	-1.21M	-2.43M	-2.82M	-1.42M
Operating Income+	-8.26M	-8.39M	-2.99M	-4.66M	-2.91M	-8.38M	-2.87M	-3.57M	-5.8M	-5.34M
Operating Margin %	-8.25%	-6.01%	-1.62%	-1.95%	-1.15%	-57.48%	-3.75%	-1.98%	-1.18%	-0.73%
Operating Income Growth %	-0.93%	-0.02%	0.64%	-0.56%	0.38%	-1.88%	0.66%	-0.24%	-0.63%	0.08%
EBITDA+	-8.26M	-8.38M	-2.98M	-4.65M	-2.89M	-8.37M	-2.84M	-3.52M	-5.76M	-5.29M
EBITDA Margin %	-8.25%	-6.01%	-1.62%	-1.95%	-1.15%	-57.45%	-3.72%	-1.95%	-1.17%	-0.73%
EBITDA Growth %	-0.93%	-0.02%	0.64%	-0.56%	0.38%	-1.9%	0.66%	-0.24%	-0.63%	0.08%
D&A (Non-Cash Add-back)	3.89K	4.92K	5.05K	5.29K	18.42K	5.04K	26.61K	48.66K	45.98K	49.69K
EBIT	-8.27M	-8.39M	-3.25M	-4.71M	-3.07M	-7.96M	-3.12M	-3.41M	-5.22M	-5.36M
Net Interest Income+	-329.44K	-81.27K	-22.96K	39	-21.63K	-4.56K	15.6K	106.67K	320.18K	128.56K
Interest Income	12.16K	16.1K	1.24K	39	0	9.2K	21.79K	116.32K	327.76K	135.87K
Interest Expense	341.6K	24.48K	24.2K	0	21.63K	13.76K	6.18K	9.65K	7.58K	7.3K
Other Income/Expense	1.19M	1.58M	-22.96K	39	-21.63K	-4.56K	15.6K	-217.67K	-1.14M	128.56K
Pretax Income+	-7.07M	-6.8M	-3.01M	-4.66M	-2.93M	-8.38M	-2.85M	-3.79M	-6.94M	-5.22M
Pretax Margin %	-7.06%	-4.87%	-1.63%	-1.95%	-1.16%	-57.52%	-3.73%	-2.1%	-1.41%	-0.72%
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-7.07M	-6.8M	-3.01M	-4.66M	-2.93M	-8.38M	-2.85M	-3.79M	-6.94M	-5.22M
Net Margin %	-7.06%	-4.87%	-1.63%	-1.95%	-1.16%	-57.52%	-3.73%	-2.1%	-1.41%	-0.72%
Net Income Growth %	-1.63%	0.04%	0.56%	-0.55%	0.37%	-1.86%	0.66%	-0.33%	-0.83%	0.25%
Net Income (Continuing)	-7.07M	-6.8M	-3.01M	-4.66M	-2.93M	-8.38M	-2.85M	-3.79M	-6.94M	-5.22M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-3.70	-2.57	-0.90	-1.29	-0.66	-1.52	-0.50	-0.66	-1.22	-0.90
EPS Growth %	-1.57%	0.31%	0.65%	-0.43%	0.49%	-1.3%	0.67%	-0.32%	-0.85%	0.26%
EPS (Basic)	-3.70	-2.57	-0.90	-1.29	-0.66	-1.52	-0.50	-0.66	-1.22	-0.90
Diluted Shares Outstanding	1.91M	2.65M	3.34M	3.62M	4.41M	5.53M	5.69M	5.69M	5.7M	5.77M
Basic Shares Outstanding	1.91M	2.65M	3.34M	3.62M	4.41M	5.53M	5.69M	5.69M	5.7M	5.77M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Total Current Assets+	8.81M	8.27M	7.05M	6.68M	4.41M	25.75M	23.67M	20.41M	14.73M	9.98M
Cash & Short-Term Investments	2.29M	3.99M	4.73M	5.12M	3.25M	25.05M	22.11M	18.99M	11.66M	5.87M
Cash Only	2.29M	3.99M	4.73M	5.12M	3.25M	25.05M	22.11M	17.16M	11.66M	2.83M
Short-Term Investments	0	0	0	0	0	0	0	1.83M	0	3.04M
Accounts Receivable	154.22K	270.13K	492.28K	298.93K	327.69K	334.71K	662.9K	417.42K	1.39M	791.39K
Days Sales Outstanding	56.23	70.62	97.5	45.7	47.49	838.05	316.2	84.42	103.3	39.64
Inventory	2.06M	2.34M	497.9K	544.34K	797.69K	292.53K	326.58K	839.97K	1.58M	1.77M
Days Inventory Outstanding	2.46K	1.8K	312.1	291.85	422.68	131.68	493.2	4.74K	369.32	256.52
Other Current Assets	4.23M	1.67M	1.33M	719.29K	33.19K	78.26K	0	0	0	-1.94M
Total Non-Current Assets+	18.06K	18.84K	20.38K	17.14K	1.79M	1.3M	1.18M	1.58M	823.63K	114.62K
Property, Plant & Equipment	18.06K	18.84K	20.38K	17.14K	70.77K	33.74K	226.74K	200.13K	154.35K	113.95K
Fixed Asset Turnover	55.42x	74.12x	90.41x	139.29x	35.59x	4.32x	3.37x	9.02x	31.77x	63.95x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	800K	0	0	0	0	0	0	159.07K	0	0
Other Non-Current Assets	-800K	-18.84K	-20.38K	-17.14K	1.72M	1.27M	956.93K	1.22M	669.28K	666
Total Assets+	8.83M	8.29M	9.24M	8.56M	6.2M	27.05M	24.86M	21.99M	15.55M	10.09M
Asset Turnover	0.11x	0.17x	0.20x	0.28x	0.41x	0.01x	0.03x	0.08x	0.32x	0.72x
Asset Growth %	0.47%	-0.06%	0.12%	-0.07%	-0.28%	3.36%	-0.08%	-0.12%	-0.29%	-0.35%
Total Current Liabilities+	3.89M	1.71M	803.34K	1.2M	516.41K	1.12M	1.5M	2.22M	2.7M	1.97M
Accounts Payable	1.52M	699.53K	216.94K	715.12K	157.64K	106.89K	720.87K	790.92K	648.85K	1.53M
Days Payables Outstanding	1.81K	538.62	135.98	383.42	83.53	48.12	1.09K	4.47K	151.23	221.36
Short-Term Debt	1.9M	365.86K	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	-1000K	19.14K	0	0	0	0	0	698.2K	0	0
Other Current Liabilities	52.06K	36.17K	472.39K	376.8K	16.02K	864.63K	535.96K	401.85K	522.57K	0
Current Ratio	2.27x	4.83x	8.78x	5.59x	8.54x	22.96x	15.75x	9.20x	5.46x	5.07x
Quick Ratio	1.74x	3.47x	8.16x	5.13x	6.99x	22.69x	15.53x	8.82x	4.87x	4.17x
Cash Conversion Cycle	699.75	1.33K	273.62	-45.86	386.64	921.62	-279.25	361.45	321.39	74.8
Total Non-Current Liabilities+	0	0	0	14.98K	41.84K	36.2K	175.45K	152.21K	141.55K	94.58K
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	18.93K	0	175.41K	150.32K	132.94K	71.86K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	14.98K	22.91K	36.2K	36	1.88K	8.61K	22.72K
Total Liabilities	3.89M	1.71M	803.34K	1.21M	558.25K	1.16M	1.68M	2.37M	2.84M	2.06M
Total Debt+	1.9M	365.86K	0	0	61.1K	20.5K	209.79K	189.09K	173.5K	117.13K
Net Debt	-390.13K	-3.63M	-4.73M	-5.12M	-3.19M	-25.03M	-21.9M	-16.97M	-11.48M	-2.71M
Debt / Equity	0.38x	0.06x	-	-	0.01x	0.00x	0.01x	0.01x	0.01x	0.01x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-24.19x	-342.65x	-123.47x	-	-134.32x	-608.96x	-464.08x	-369.75x	-765.72x	-731.63x
Total Equity+	4.94M	6.57M	8.44M	7.35M	5.64M	25.9M	23.18M	19.62M	12.71M	8.03M
Equity Growth %	0.03%	0.33%	0.28%	-0.13%	-0.23%	3.59%	-0.1%	-0.15%	-0.35%	-0.37%
Book Value per Share	2.59	2.48	2.53	2.03	1.28	4.69	4.07	3.44	2.23	1.39
Total Shareholders' Equity	4.94M	6.57M	8.44M	7.35M	5.64M	25.9M	23.18M	19.62M	12.71M	8.03M
Common Stock	45.63M	53.63M	58.37M	60.29M	62.43M	88.36M	88.44M	88.44M	88.5M	88.87M
Retained Earnings	-42.82M	-49.53M	-52.54M	-57.24M	-57.92M	-65.93M	-68.43M	-72.06M	-78.97M	-82.48M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	2.13M	2.47M	2.61M	4.3M	1.13M	3.47M	3.17M	3.24M	3.17M	1.64M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Cash from Operations+	-3.75M	-7.03M	-3.5M	-1.29M	-3.16M	-3.05M	-3.13M	-2.49M	-5.88M	-6.14M
Operating CF Margin %	-3.75%	-5.04%	-1.9%	-0.54%	-1.26%	-20.89%	-4.09%	-1.38%	-1.2%	-0.84%
Operating CF Growth %	-0.24%	-0.87%	0.5%	0.63%	-1.46%	0.04%	-0.03%	0.21%	-1.36%	-0.04%
Net Income	-4.07M	-6.8M	-3.01M	-3.33M	-2.93M	-6.25M	-2.85M	-3.79M	-6.94M	-5.22M
Depreciation & Amortization	2.83K	4.92K	5.05K	3.78K	44.06K	32.57K	26.61K	48.66K	0	49.69K
Stock-Based Compensation	0	522.66K	242.95K	0	-533.91K	0	94.89K	226.95K	0	304.24K
Deferred Taxes	0	0	-347.31K	0	610.96K	0	76.11K	-842.14K	0	0
Other Non-Cash Items	1.64M	-481.86K	-498.64K	994.14K	-539.93K	2.04M	-205.63K	465.6K	2.03M	-753.38K
Working Capital Changes	-1.33M	-793.42K	104.36K	1.05M	181.26K	1.14M	-269.92K	1.4M	-974.81K	-521.51K
Change in Receivables	-1.13M	7.4K	438K	486.55K	641.24K	17.18K	-337K	226.37K	-958.47K	-557.25K
Change in Inventory	-662.06K	-280.06K	-333.64K	188.35K	-113.64K	716.79K	275.61K	-776.1K	-194.28K	480.86K
Change in Payables	489.43K	-559.45K	-620.2K	304.85K	-362.44K	437.72K	285.62K	31.88K	0	0
Cash from Investing+	-1.78K	-5.7K	-5.32K	-1.46K	-864	-4.95K	11.74K	-2.74M	327.56K	-2.9M
Capital Expenditures	-1.78K	-5.7K	-6.59K	-1.46K	-864	-4.95K	-10.05K	-7.74K	-195	0
CapEx % of Revenue	0%	0%	0%	0%	0%	0.03%	0.01%	0%	0%	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	1.28K	0	0	0	21.79K	-2.61M	327.76K	-2.9M
Cash from Financing+	3.15M	8.7M	4.35M	1.48M	1.17M	19.76M	-36.26K	-35.02K	829	199.75K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	-1.69M	-757.35K	0	-41.39K	-30.29K	0	0	-7.58K	-131.42K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-3.76M	-7.04M	-3.51M	-1.29M	-3.17M	-3.05M	-3.14M	-2.5M	-5.88M	-6.14M
FCF Margin %	-3.75%	-5.04%	-1.91%	-0.54%	-1.26%	-20.93%	-4.11%	-1.38%	-1.2%	-0.84%
FCF Growth %	-0.24%	-0.87%	0.5%	0.63%	-1.46%	0.04%	-0.03%	0.21%	-1.36%	-0.04%
FCF per Share	-1.97	-2.66	-1.05	-0.36	-0.72	-0.55	-0.55	-0.44	-1.03	-1.06
FCF Conversion (FCF/Net Income)	0.53x	1.03x	1.16x	0.28x	1.08x	0.36x	1.10x	0.66x	0.85x	1.18x
Interest Paid	0	0	0	0	0	0	0	0	0	7.3K
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-144.98%	-118.17%	-40.11%	-58.98%	-45.05%	-53.17%	-11.63%	-17.7%	-42.92%	-50.3%
Return on Invested Capital (ROIC)	-198.45%	-167.87%	-67.32%	-117.52%	-93.01%	-378.29%	-200.67%	-136.46%	-224.75%	-122.51%
Gross Margin	69.47%	66.05%	68.4%	71.49%	72.65%	-456.22%	68.41%	96.42%	68.06%	65.39%
Net Margin	-706.12%	-487.33%	-163.38%	-195.04%	-116.23%	-5751.61%	-373.01%	-209.81%	-141.49%	-71.58%
Debt / Equity	0.38x	0.06x	-	-	0.01x	0.00x	0.01x	0.01x	0.01x	0.01x
Interest Coverage	-24.19x	-342.65x	-123.47x	-	-134.32x	-608.96x	-464.08x	-369.75x	-765.72x	-731.63x
FCF Conversion	0.53x	1.03x	1.16x	0.28x	1.08x	0.36x	1.10x	0.66x	0.85x	1.18x
Revenue Growth	-0.13%	39.47%	31.99%	29.55%	5.49%	-94.21%	424.91%	135.85%	171.67%	48.63%

Revenue by Segment

	2019	2020	2021
ProtectynMember	-	-	50.18K
ProtectynMember Growth	-	-	-
Protectyn	59.05K	49.93K	-
Protectyn Growth	-	-15.44%	-
Travelan	2.33M	-	-
Travelan Growth	-	-	-

Frequently Asked Questions

Growth & Financials

Immuron Limited (IMRN) reported $10.9M in revenue for fiscal year 2025. This represents a 2334% increase from $0.4M in 2012.

Immuron Limited (IMRN) grew revenue by 48.6% over the past year. This is strong growth.

Immuron Limited (IMRN) reported a net loss of $7.9M for fiscal year 2025.

Dividend & Returns

Immuron Limited (IMRN) has a return on equity (ROE) of -50.3%. Negative ROE indicates the company is unprofitable.

Immuron Limited (IMRN) had negative free cash flow of $9.2M in fiscal year 2025, likely due to heavy capital investments.

US Stock Screener

...

Immuron Limited (IMRN) 10-Year Financial Performance & Capital Metrics

IMRN • • Industrial / General

HealthcareBiotechnologyInfectious DiseasesAntibiotics & Bacterial Infections

Revenue $7M +48.6%
EBITDA -$5M +8.0%
Net Income -$5M +24.8%
EPS (Diluted) -0.90 +26.2%
Gross Margin 65.39% -3.9%
EBITDA Margin -72.66% +38.1%
Operating Margin -73.34% +38.0%
Net Margin -71.58% +49.4%
ROE -50.3% -17.2%
ROIC -122.51% +45.5%
Debt/Equity 0.01 +6.8%
Interest Coverage -731.63 +4.5%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Strong 5Y sales CAGR of 23.7%
✓Trading at only 0.8x book value

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Negative free cash flow
✗Weak momentum: RS Rating 6 (bottom 6%)
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y21.94%

5Y23.67%

3Y111.96%

TTM61.05%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM23.48%

EPS CAGR

10Y-

5Y-

3Y-

TTM25.41%

ROCE

10Y Avg-62.61%

5Y Avg-33.55%

3Y Avg-34.36%

Latest-50.96%

Peer Comparison

Antibiotics & Bacterial Infections

Name	Market Cap	Current Price	P/E Ratio	Net Margin	ROE	Debt/Equity
PLRZPolyrizon Ltd.	16.19M	15.54	31.08		-5.21%
TOVXTheriva Biologics, Inc.	7.49M	0.21	-0.01		-388.69%	0.08
CTXRCitius Pharmaceuticals, Inc.	17.79M	0.86	-0.14	-258.23%	-59.6%	0.00
ACXPAcurx Pharmaceuticals, Inc.	6.32M	2.69	-0.15		-0.25%
ITRMIterum Therapeutics plc	17.16M	0.32	-0.26	-69.13%
ANTXAN2 Therapeutics, Inc.	34.25M	1.25	-0.73		-56.29%
MCRBSeres Therapeutics, Inc.	137.33M	15.18	-0.80	15.37%	12.34%	6.65
PYPDPolyPid Ltd.	73.03M	4.39	-0.89		-10.39%	1.25

Profit & Loss

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Sales/Revenue+	1M	1.4M	1.84M	2.39M	2.52M	145.78K	765.19K	1.8M	4.9M	7.29M
Revenue Growth %	-0%	0.39%	0.32%	0.3%	0.05%	-0.94%	4.25%	1.36%	1.72%	0.49%
Cost of Goods Sold+	305.61K	474.04K	582.29K	680.76K	688.84K	810.84K	241.69K	64.63K	1.57M	2.52M
COGS % of Revenue	0.31%	0.34%	0.32%	0.29%	0.27%	5.56%	0.32%	0.04%	0.32%	0.35%
Gross Profit+	695.47K	922.16K	1.26M	1.71M	1.83M	-665.06K	523.5K	1.74M	3.34M	4.77M
Gross Margin %	0.69%	0.66%	0.68%	0.71%	0.73%	-4.56%	0.68%	0.96%	0.68%	0.65%
Gross Profit Growth %	0.07%	0.33%	0.37%	0.35%	0.07%	-1.36%	1.79%	2.32%	0.92%	0.43%
Operating Expenses+	8.96M	9.31M	4.25M	6.36M	4.74M	7.71M	3.39M	5.31M	9.14M	10.11M
OpEx % of Revenue	8.95%	6.67%	2.31%	2.67%	1.88%	52.92%	4.43%	2.94%	1.86%	1.39%
Selling, General & Admin	5.33M	4.68M	4.1M	5.9M	4.04M	6.38M	3.94M	5.15M	6.59M	7.94M
SG&A % of Revenue	5.33%	3.35%	2.22%	2.47%	1.6%	43.78%	5.15%	2.85%	1.34%	1.09%
Research & Development	3.62M	4.63M	2.26M	1.04M	1.18M	1.37M	657.72K	2.59M	5.38M	3.6M
R&D % of Revenue	3.62%	3.32%	1.22%	0.44%	0.47%	9.38%	0.86%	1.44%	1.1%	0.49%
Other Operating Expenses	0	0	-2.11M	-583.86K	-485.01K	-34.58K	-1.21M	-2.43M	-2.82M	-1.42M
Operating Income+	-8.26M	-8.39M	-2.99M	-4.66M	-2.91M	-8.38M	-2.87M	-3.57M	-5.8M	-5.34M
Operating Margin %	-8.25%	-6.01%	-1.62%	-1.95%	-1.15%	-57.48%	-3.75%	-1.98%	-1.18%	-0.73%
Operating Income Growth %	-0.93%	-0.02%	0.64%	-0.56%	0.38%	-1.88%	0.66%	-0.24%	-0.63%	0.08%
EBITDA+	-8.26M	-8.38M	-2.98M	-4.65M	-2.89M	-8.37M	-2.84M	-3.52M	-5.76M	-5.29M
EBITDA Margin %	-8.25%	-6.01%	-1.62%	-1.95%	-1.15%	-57.45%	-3.72%	-1.95%	-1.17%	-0.73%
EBITDA Growth %	-0.93%	-0.02%	0.64%	-0.56%	0.38%	-1.9%	0.66%	-0.24%	-0.63%	0.08%
D&A (Non-Cash Add-back)	3.89K	4.92K	5.05K	5.29K	18.42K	5.04K	26.61K	48.66K	45.98K	49.69K
EBIT	-8.27M	-8.39M	-3.25M	-4.71M	-3.07M	-7.96M	-3.12M	-3.41M	-5.22M	-5.36M
Net Interest Income+	-329.44K	-81.27K	-22.96K	39	-21.63K	-4.56K	15.6K	106.67K	320.18K	128.56K
Interest Income	12.16K	16.1K	1.24K	39	0	9.2K	21.79K	116.32K	327.76K	135.87K
Interest Expense	341.6K	24.48K	24.2K	0	21.63K	13.76K	6.18K	9.65K	7.58K	7.3K
Other Income/Expense	1.19M	1.58M	-22.96K	39	-21.63K	-4.56K	15.6K	-217.67K	-1.14M	128.56K
Pretax Income+	-7.07M	-6.8M	-3.01M	-4.66M	-2.93M	-8.38M	-2.85M	-3.79M	-6.94M	-5.22M
Pretax Margin %	-7.06%	-4.87%	-1.63%	-1.95%	-1.16%	-57.52%	-3.73%	-2.1%	-1.41%	-0.72%
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-7.07M	-6.8M	-3.01M	-4.66M	-2.93M	-8.38M	-2.85M	-3.79M	-6.94M	-5.22M
Net Margin %	-7.06%	-4.87%	-1.63%	-1.95%	-1.16%	-57.52%	-3.73%	-2.1%	-1.41%	-0.72%
Net Income Growth %	-1.63%	0.04%	0.56%	-0.55%	0.37%	-1.86%	0.66%	-0.33%	-0.83%	0.25%
Net Income (Continuing)	-7.07M	-6.8M	-3.01M	-4.66M	-2.93M	-8.38M	-2.85M	-3.79M	-6.94M	-5.22M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-3.70	-2.57	-0.90	-1.29	-0.66	-1.52	-0.50	-0.66	-1.22	-0.90
EPS Growth %	-1.57%	0.31%	0.65%	-0.43%	0.49%	-1.3%	0.67%	-0.32%	-0.85%	0.26%
EPS (Basic)	-3.70	-2.57	-0.90	-1.29	-0.66	-1.52	-0.50	-0.66	-1.22	-0.90
Diluted Shares Outstanding	1.91M	2.65M	3.34M	3.62M	4.41M	5.53M	5.69M	5.69M	5.7M	5.77M
Basic Shares Outstanding	1.91M	2.65M	3.34M	3.62M	4.41M	5.53M	5.69M	5.69M	5.7M	5.77M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Total Current Assets+	8.81M	8.27M	7.05M	6.68M	4.41M	25.75M	23.67M	20.41M	14.73M	9.98M
Cash & Short-Term Investments	2.29M	3.99M	4.73M	5.12M	3.25M	25.05M	22.11M	18.99M	11.66M	5.87M
Cash Only	2.29M	3.99M	4.73M	5.12M	3.25M	25.05M	22.11M	17.16M	11.66M	2.83M
Short-Term Investments	0	0	0	0	0	0	0	1.83M	0	3.04M
Accounts Receivable	154.22K	270.13K	492.28K	298.93K	327.69K	334.71K	662.9K	417.42K	1.39M	791.39K
Days Sales Outstanding	56.23	70.62	97.5	45.7	47.49	838.05	316.2	84.42	103.3	39.64
Inventory	2.06M	2.34M	497.9K	544.34K	797.69K	292.53K	326.58K	839.97K	1.58M	1.77M
Days Inventory Outstanding	2.46K	1.8K	312.1	291.85	422.68	131.68	493.2	4.74K	369.32	256.52
Other Current Assets	4.23M	1.67M	1.33M	719.29K	33.19K	78.26K	0	0	0	-1.94M
Total Non-Current Assets+	18.06K	18.84K	20.38K	17.14K	1.79M	1.3M	1.18M	1.58M	823.63K	114.62K
Property, Plant & Equipment	18.06K	18.84K	20.38K	17.14K	70.77K	33.74K	226.74K	200.13K	154.35K	113.95K
Fixed Asset Turnover	55.42x	74.12x	90.41x	139.29x	35.59x	4.32x	3.37x	9.02x	31.77x	63.95x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	800K	0	0	0	0	0	0	159.07K	0	0
Other Non-Current Assets	-800K	-18.84K	-20.38K	-17.14K	1.72M	1.27M	956.93K	1.22M	669.28K	666
Total Assets+	8.83M	8.29M	9.24M	8.56M	6.2M	27.05M	24.86M	21.99M	15.55M	10.09M
Asset Turnover	0.11x	0.17x	0.20x	0.28x	0.41x	0.01x	0.03x	0.08x	0.32x	0.72x
Asset Growth %	0.47%	-0.06%	0.12%	-0.07%	-0.28%	3.36%	-0.08%	-0.12%	-0.29%	-0.35%
Total Current Liabilities+	3.89M	1.71M	803.34K	1.2M	516.41K	1.12M	1.5M	2.22M	2.7M	1.97M
Accounts Payable	1.52M	699.53K	216.94K	715.12K	157.64K	106.89K	720.87K	790.92K	648.85K	1.53M
Days Payables Outstanding	1.81K	538.62	135.98	383.42	83.53	48.12	1.09K	4.47K	151.23	221.36
Short-Term Debt	1.9M	365.86K	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	-1000K	19.14K	0	0	0	0	0	698.2K	0	0
Other Current Liabilities	52.06K	36.17K	472.39K	376.8K	16.02K	864.63K	535.96K	401.85K	522.57K	0
Current Ratio	2.27x	4.83x	8.78x	5.59x	8.54x	22.96x	15.75x	9.20x	5.46x	5.07x
Quick Ratio	1.74x	3.47x	8.16x	5.13x	6.99x	22.69x	15.53x	8.82x	4.87x	4.17x
Cash Conversion Cycle	699.75	1.33K	273.62	-45.86	386.64	921.62	-279.25	361.45	321.39	74.8
Total Non-Current Liabilities+	0	0	0	14.98K	41.84K	36.2K	175.45K	152.21K	141.55K	94.58K
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	18.93K	0	175.41K	150.32K	132.94K	71.86K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	14.98K	22.91K	36.2K	36	1.88K	8.61K	22.72K
Total Liabilities	3.89M	1.71M	803.34K	1.21M	558.25K	1.16M	1.68M	2.37M	2.84M	2.06M
Total Debt+	1.9M	365.86K	0	0	61.1K	20.5K	209.79K	189.09K	173.5K	117.13K
Net Debt	-390.13K	-3.63M	-4.73M	-5.12M	-3.19M	-25.03M	-21.9M	-16.97M	-11.48M	-2.71M
Debt / Equity	0.38x	0.06x	-	-	0.01x	0.00x	0.01x	0.01x	0.01x	0.01x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-24.19x	-342.65x	-123.47x	-	-134.32x	-608.96x	-464.08x	-369.75x	-765.72x	-731.63x
Total Equity+	4.94M	6.57M	8.44M	7.35M	5.64M	25.9M	23.18M	19.62M	12.71M	8.03M
Equity Growth %	0.03%	0.33%	0.28%	-0.13%	-0.23%	3.59%	-0.1%	-0.15%	-0.35%	-0.37%
Book Value per Share	2.59	2.48	2.53	2.03	1.28	4.69	4.07	3.44	2.23	1.39
Total Shareholders' Equity	4.94M	6.57M	8.44M	7.35M	5.64M	25.9M	23.18M	19.62M	12.71M	8.03M
Common Stock	45.63M	53.63M	58.37M	60.29M	62.43M	88.36M	88.44M	88.44M	88.5M	88.87M
Retained Earnings	-42.82M	-49.53M	-52.54M	-57.24M	-57.92M	-65.93M	-68.43M	-72.06M	-78.97M	-82.48M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	2.13M	2.47M	2.61M	4.3M	1.13M	3.47M	3.17M	3.24M	3.17M	1.64M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Cash from Operations+	-3.75M	-7.03M	-3.5M	-1.29M	-3.16M	-3.05M	-3.13M	-2.49M	-5.88M	-6.14M
Operating CF Margin %	-3.75%	-5.04%	-1.9%	-0.54%	-1.26%	-20.89%	-4.09%	-1.38%	-1.2%	-0.84%
Operating CF Growth %	-0.24%	-0.87%	0.5%	0.63%	-1.46%	0.04%	-0.03%	0.21%	-1.36%	-0.04%
Net Income	-4.07M	-6.8M	-3.01M	-3.33M	-2.93M	-6.25M	-2.85M	-3.79M	-6.94M	-5.22M
Depreciation & Amortization	2.83K	4.92K	5.05K	3.78K	44.06K	32.57K	26.61K	48.66K	0	49.69K
Stock-Based Compensation	0	522.66K	242.95K	0	-533.91K	0	94.89K	226.95K	0	304.24K
Deferred Taxes	0	0	-347.31K	0	610.96K	0	76.11K	-842.14K	0	0
Other Non-Cash Items	1.64M	-481.86K	-498.64K	994.14K	-539.93K	2.04M	-205.63K	465.6K	2.03M	-753.38K
Working Capital Changes	-1.33M	-793.42K	104.36K	1.05M	181.26K	1.14M	-269.92K	1.4M	-974.81K	-521.51K
Change in Receivables	-1.13M	7.4K	438K	486.55K	641.24K	17.18K	-337K	226.37K	-958.47K	-557.25K
Change in Inventory	-662.06K	-280.06K	-333.64K	188.35K	-113.64K	716.79K	275.61K	-776.1K	-194.28K	480.86K
Change in Payables	489.43K	-559.45K	-620.2K	304.85K	-362.44K	437.72K	285.62K	31.88K	0	0
Cash from Investing+	-1.78K	-5.7K	-5.32K	-1.46K	-864	-4.95K	11.74K	-2.74M	327.56K	-2.9M
Capital Expenditures	-1.78K	-5.7K	-6.59K	-1.46K	-864	-4.95K	-10.05K	-7.74K	-195	0
CapEx % of Revenue	0%	0%	0%	0%	0%	0.03%	0.01%	0%	0%	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	1.28K	0	0	0	21.79K	-2.61M	327.76K	-2.9M
Cash from Financing+	3.15M	8.7M	4.35M	1.48M	1.17M	19.76M	-36.26K	-35.02K	829	199.75K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	-1.69M	-757.35K	0	-41.39K	-30.29K	0	0	-7.58K	-131.42K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-3.76M	-7.04M	-3.51M	-1.29M	-3.17M	-3.05M	-3.14M	-2.5M	-5.88M	-6.14M
FCF Margin %	-3.75%	-5.04%	-1.91%	-0.54%	-1.26%	-20.93%	-4.11%	-1.38%	-1.2%	-0.84%
FCF Growth %	-0.24%	-0.87%	0.5%	0.63%	-1.46%	0.04%	-0.03%	0.21%	-1.36%	-0.04%
FCF per Share	-1.97	-2.66	-1.05	-0.36	-0.72	-0.55	-0.55	-0.44	-1.03	-1.06
FCF Conversion (FCF/Net Income)	0.53x	1.03x	1.16x	0.28x	1.08x	0.36x	1.10x	0.66x	0.85x	1.18x
Interest Paid	0	0	0	0	0	0	0	0	0	7.3K
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-144.98%	-118.17%	-40.11%	-58.98%	-45.05%	-53.17%	-11.63%	-17.7%	-42.92%	-50.3%
Return on Invested Capital (ROIC)	-198.45%	-167.87%	-67.32%	-117.52%	-93.01%	-378.29%	-200.67%	-136.46%	-224.75%	-122.51%
Gross Margin	69.47%	66.05%	68.4%	71.49%	72.65%	-456.22%	68.41%	96.42%	68.06%	65.39%
Net Margin	-706.12%	-487.33%	-163.38%	-195.04%	-116.23%	-5751.61%	-373.01%	-209.81%	-141.49%	-71.58%
Debt / Equity	0.38x	0.06x	-	-	0.01x	0.00x	0.01x	0.01x	0.01x	0.01x
Interest Coverage	-24.19x	-342.65x	-123.47x	-	-134.32x	-608.96x	-464.08x	-369.75x	-765.72x	-731.63x
FCF Conversion	0.53x	1.03x	1.16x	0.28x	1.08x	0.36x	1.10x	0.66x	0.85x	1.18x
Revenue Growth	-0.13%	39.47%	31.99%	29.55%	5.49%	-94.21%	424.91%	135.85%	171.67%	48.63%

Revenue by Segment

	2019	2020	2021
ProtectynMember	-	-	50.18K
ProtectynMember Growth	-	-	-
Protectyn	59.05K	49.93K	-
Protectyn Growth	-	-15.44%	-
Travelan	2.33M	-	-
Travelan Growth	-	-	-

Frequently Asked Questions

Growth & Financials

Immuron Limited (IMRN) reported $10.9M in revenue for fiscal year 2025. This represents a 2334% increase from $0.4M in 2012.

Immuron Limited (IMRN) grew revenue by 48.6% over the past year. This is strong growth.

Immuron Limited (IMRN) reported a net loss of $7.9M for fiscal year 2025.

Dividend & Returns

Immuron Limited (IMRN) has a return on equity (ROE) of -50.3%. Negative ROE indicates the company is unprofitable.

Immuron Limited (IMRN) had negative free cash flow of $9.2M in fiscal year 2025, likely due to heavy capital investments.